Role of Sub-Conjunctival Bevacizumab in Post Pterygium Excision Management
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Enrollment
- 31
- Locations
- 1
- Primary Endpoint
- number of recurrent pterygia with postoperative bevacizumab
Study Overview
Brief Summary
A pterygium is a fibrovascular growth originating from the conjunctiva that grows onto the surface of the cornea. Frequently, these pterygia will recur even after surgical resection. Bevacizumab is an inhibitor of angiogenesis, which is needed for recurrent growth. The use of bevacizumab is poorly understood in inhibiting pterygium growth. The objective of this study is to compare the effects of wound healing and recurrence rates in postoperative bevacizumab versus pterygium excision alone.
Detailed Description
This is a prospective trial. Thirty-one patients with a primary pterygium of at least 2 mm in size and without any previous ocular surgery will be included. Outcome measures will include best corrected visual acuity, intraocular pressure, recurrence, and any sight threatening complications at two weeks, two months, and six months postoperatively.
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Primary Purpose
- Treatment
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •any patient 18 years of age or older with a primary pterygium that extends at least 2 mm past the limbus
Exclusion Criteria
- •history of glaucoma
- •previous ocular surgery
- •steroid-response glaucoma
- •previous myocardial infarct
- •bleeding disorder
- •pregnancy
- •lack of patient cooperation
Arms & Interventions
Pterygium Excision with Bevacizumab Injection
Intervention: Bevacizumab (Drug)
Outcomes
Primary Outcomes
number of recurrent pterygia with postoperative bevacizumab
Time Frame: 6 months
The number of recurrent pterygia with patients who received bevacizumab after pterygium excision was compared to the number of recurrences in those patients who only had pterygium excision.
Secondary Outcomes
No secondary outcomes reported
Investigators
Sonia Dhoot
Prinicipal Investigator
Arrowhead Regional Medical Center